454 related articles for article (PubMed ID: 29217412)
1. Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins.
Hasegawa Y; Hori M; Nakagami T; Harada-Shiba M; Uchigata Y
J Clin Lipidol; 2018; 12(1):62-69.e1. PubMed ID: 29217412
[TBL] [Abstract][Full Text] [Related]
2. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
[TBL] [Abstract][Full Text] [Related]
3. Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes.
Singhal M; Unni S; Schauerhamer M; Nguyen H; Hurd J; McAdam-Marx C
J Manag Care Spec Pharm; 2017 Mar; 23(3):267-275. PubMed ID: 28230449
[TBL] [Abstract][Full Text] [Related]
4. Real-world use of glucagon-like peptide-1 receptor agonists in youth with type 2 diabetes is associated with short-term improvements in HbA1c.
Samuels SL; Chajecki A; Hu P; Kayser M; Weyman K; Pan B; Brown EA; Van Name M; Wolf RM
Diabetes Obes Metab; 2024 Apr; 26(4):1305-1313. PubMed ID: 38229444
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes:real-world evidence from a Mediterranean area.
Mata-Cases M; Franch-Nadal J; Ortega E; Real J; Gratacòs M; Vlacho B; Mauricio D
Curr Med Res Opin; 2019 Oct; 35(10):1735-1744. PubMed ID: 31081693
[No Abstract] [Full Text] [Related]
6. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients.
Montvida O; Klein K; Kumar S; Khunti K; Paul SK
Diabetes Obes Metab; 2017 Jan; 19(1):108-117. PubMed ID: 27629433
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
Yuan S; Wu Y
Front Public Health; 2023; 11():1201818. PubMed ID: 37744474
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
Patoulias D; Katsimardou A; Kalogirou MS; Zografou I; Toumpourleka M; Imprialos K; Stavropoulos K; Stergiou I; Papadopoulos C; Doumas M
Diabetes Metab; 2020 Sep; 46(4):272-279. PubMed ID: 32437914
[TBL] [Abstract][Full Text] [Related]
9. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM).
Gourdy P; Darmon P; Dievart F; Halimi JM; Guerci B
Cardiovasc Diabetol; 2023 Apr; 22(1):79. PubMed ID: 37005640
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.
Yao H; Zhang A; Li D; Wu Y; Wang CZ; Wan JY; Yuan CS
BMJ; 2024 Jan; 384():e076410. PubMed ID: 38286487
[TBL] [Abstract][Full Text] [Related]
12. Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.
Tsukamoto S; Tanaka S; Yamada T; Uneda K; Azushima K; Kinguchi S; Wakui H; Tamura K
Diabetes Obes Metab; 2024 Jan; 26(1):262-274. PubMed ID: 37828829
[TBL] [Abstract][Full Text] [Related]
13. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States.
Johnston SS; Nguyen H; Felber E; Cappell K; Nelson JK; Chu BC; Kalsekar I
Adv Ther; 2014 Nov; 31(11):1119-33. PubMed ID: 25408484
[TBL] [Abstract][Full Text] [Related]
14. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
Sloan LA
J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
[TBL] [Abstract][Full Text] [Related]
15. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
Brunton SA; Wysham CH
Postgrad Med; 2020 Nov; 132(sup2):3-14. PubMed ID: 32815454
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
17. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
Nowrouzi-Sohrabi P; Rezaei S; Jalali M; Ashourpour M; Ahmadipour A; Keshavarz P; Akbari H
Eur J Pharmacol; 2021 Feb; 893():173823. PubMed ID: 33352183
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
[TBL] [Abstract][Full Text] [Related]
19. Real-world use of glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes: A retrospective database study (DEFINE-G).
Ohsugi M; Eguchi K; Thietje Mortensen J; Yamamoto Y; Ueki K
Diabetes Res Clin Pract; 2023 Sep; 203():110841. PubMed ID: 37481115
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of GLP-1 receptor agonists in type 2 diabetic patients: A retrospective real-life study in 131 patients.
Hemmer A; Maiter D; Buysschaert M; Preumont V
Diabetes Metab Syndr; 2019; 13(1):332-336. PubMed ID: 30641721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
